Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.55 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.55 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.55 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | TERT | O14746 | 5/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.43 |
| ▸ | CD40 | P25942 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.39 |
| ▸ | CHRNG | P07510 | 2/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.39 |
| ▸ | CHRND | Q07001 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18653794 | 1.00 | GNAI3 (0.55) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL14916812 | 1.00 | GNAI3 (0.55) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL20272608 | 0.99 | GNAI3 (0.57) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL20706553 | 0.99 | GNAI3 (0.57) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL14240716 | 0.96 | GNAI3 (0.51) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL14240586 | 0.95 | GNAI3 (0.50) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL14616413 | 0.94 | GNAI3 (0.59) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL14616462 | 0.94 | GNAI3 (0.59) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL14616485 | 0.94 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TLR2TERT | |
| SCHEMBL14616412 | 0.94 | GNAI3 (0.52) | GNAI3GNAO1GNAI1TLR2TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4171577-B1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL MYERS SQUIBB CO (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12522561-B2 | Process for synthesizing cationic lipids | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230265050-A1 | PROCESS FOR SYNTHESIZING CATIONIC LIPIDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-24 | — | — | US | disclosed |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
| EP-4171577-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | Bristol-Myers Squibb Company (US) | 2023-05-03 | — | — | EP | disclosed |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2020-06-02 | — | — | US | disclosed |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | NITTO DENKO CORPORATION (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-2998289-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2019-08-07 | — | — | EP | disclosed |
| EP-2998289-B1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORP (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-10196637-B2 | Retinoid-lipid drug carrier | NITTO DENKO CORPORATION (JP) | 2019-02-05 | — | — | US | disclosed |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | NITTO DENKO CORPORATION (JP) | 2013-08-15 | — | — | US | disclosed |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | NITTO DENKO CORPORATION (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171240-A1 | DRUG CARRIER AND DRUG CARRIER KIT FOR INHIBITING FIBROSIS | KIT, STRA6, HAVCR2 | GNAI3 2230/4885GNAO1 1687/4885GNAI1 1803/4885 |
| US-20230265050-A1 | PROCESS FOR SYNTHESIZING CATIONIC LIPIDS | PLIN1, FABP4, PLIN3 | GNAI3 2327/4885GNAO1 3410/4885GNAI1 1438/4885 |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | GNAI3 3017/4885GNAO1 3483/4885GNAI1 2976/4885 |
| US-20130171127-A1 | COMPOSITION FOR REGENERATING NORMAL TISSUE FROM FIBROTIC TISSUE | COL1A1, COL2A1, COL14A1 | GNAI3 3045/4885GNAO1 3787/4885GNAI1 2852/4885 |
| US-20230250053-A1 | PROCESS FOR SYNTHESIZING TARGETING MOLECULES | RARG, RARA, RARB | GNAI3 1747/4885GNAO1 2144/4885GNAI1 1147/4885 |
| US-10669229-B2 | Compounds for targeting drug delivery and enhancing siRNA activity | LDLR, RARG, FABP4 | GNAI3 3017/4885GNAO1 3483/4885GNAI1 2976/4885 |
| US-20130210744-A1 | TARGETING AGENT FOR CANCER CELL OR CANCER-ASSOCIATED FIBROBLAST | FGFR2, FRS2, FOLR1 | GNAI3 1556/4885GNAO1 2122/4885GNAI1 1632/4885 |
| US-10196637-B2 | Retinoid-lipid drug carrier | RXRA, RXRG, LRAT | GNAI3 3028/4885GNAO1 3716/4885GNAI1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.